In collaboration with The Rosalind Franklin Institute, we have been detecting a tiny peptide that could diagnose Alzheimer’s disease at an early stage, an SME focusing on therapeutics for neurodegenerative disease. Together, we were able to use our Mass Spectrometry technology to detect and quantify a novel molecule, associated with cognitive decline, in saliva samples
Click here to read the full paper